Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model • Weekly administration of single agent sudocetaxel zendusortide demonstrated…#antipdl1 #weekly #preclinical #montreal #theratechnologiesinc #theratechnologies #sortilin #sort1 #christianmarsolais #phd
Source: Reuters: Health - Category: Consumer Health News Source Type: news